RecruitingPhase 3NCT06003387
Blood
Severe hemophilia B
6
studies recruiting now
as of 7 Sept 2026
79
studies registered in total
as of 7 Sept 2026
32
countries with a recruiting site
as of 7 Sept 2026
23 Jul 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT05611801
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RecruitingPhase 1 / Phase 2NCT06379789
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RecruitingPhase 3NCT07080905
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RecruitingPhase 3NCT05145127
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 6 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Severe hemophilia B study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Severe hemophilia B
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (F9).
Treatments being studied
1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Eftrenonacog Alfa (Alprolix)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).